The company’s intein-based technology is initially aimed at Stargardt disease, a type of macular degeneration.

The financing will support the ongoing interventional Phase I/II ASTRA trial and the observational POLARIS study of SB-007.

Panelists discuss how splice modifiers work by enhancing protein production from the SMN2 gene, with risdiplam (Evrysdi) being an oral daily medication and nusinersen (Spinraza) being administered ...

Spain’s SpliceBio will use $135 million from a series B round backed by Sanofi and Roche to advance its lead gene editing ...

Between the 1996 version of Resident Evil and it's 2002 remake, several aspects of the lore were changed. Largely, these were ...

The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Department of Radiation Oncology and Molecular Radiation Sciences ...

Spanish biotech SpliceBio has secured $135 million in series B financing to accelerate development of its experimental gene ...

SpliceBio's lead in-house pipeline project is in Stargardt disease, an IRD with no approved therapies that is caused by ...

PepGen leverages a graph-based approach to improve the detection of hidden protein variants in a computationally efficient ...

By affecting which form of a gene is expressed, alternative splicing is a major source of diversity in the nervous system. Here, the authors present an atlas of splice variants across neurons ...